Clinical Trial Update: Dose De-escalation to the Elective Nodal Sites in Head and Neck Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating dose de-escalation to elective nodal sites in head and neck cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Head and Neck Cancer | Phase 3 | Status: COMPLETED